Subtype
Neuroblastoma
CI-CAN-00003408Explore in graph →
137 active trials3 approved drugs27 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003408Explore in graph →
Clinical trials
616 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (80)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01576692 | Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma | completed | Phase 1 | 34 | St. Jude Children's Research HospitalOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00960063 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | terminated | Phase 1 | 4 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 |
| clinicaltrials |
| NCT02337309 | SF1126 for Patients With Relapsed or Refractory Neuroblastoma | terminated | Phase 1 | 4 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Aug 20, 2018 | clinicaltrials |
| NCT01462396 | Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors(STALLO) | completed | Phase 1 | 4 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00923351 | Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma | completed | Phase 1 / Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2018 | clinicaltrials |
| NCT03242603 | Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells(NKEXPGD2) | unknown | Phase 1 / Phase 2 | 5 | National University Hospital, SingaporeOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT00931931 | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | completed | Phase 1 | 18 | Timothy CripeOTHER | 1 | Mar 21, 2018 | clinicaltrials |
| NCT02130869 | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | completed | Phase 1 | 8 | St. Jude Children's Research HospitalOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT02164097 | ODSH + ICE Chemotherapy in Pediatric Solid Tumors | terminated | Phase 1 | 4 | New York Medical CollegeOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT00003926 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | terminated | Phase 1 | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00944580 | A Vaccine Study for High Risk Cancers | withdrawn | Phase 1 | 0 | Penn State UniversityOTHER | 0 | Nov 24, 2017 | clinicaltrials |
| NCT02745756 | A Combined Cell Therapy Approach to the Treatment of Neuroblastoma | withdrawn | Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Aug 30, 2017 | clinicaltrials |
| NCT00743496 | A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma | completed | Phase 1 | 50 | St. Jude Children's Research HospitalOTHER | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00644696 | Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma | completed | Phase 1 | 18 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 6, 2017 | clinicaltrials |
| NCT01130623 | A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01132911 | A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas | completed | Phase 1 | 5 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT02439788 | 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA(GINAKIT) | withdrawn | Phase 1 | 0 | Baylor College of MedicineOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01288573 | A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone | completed | Phase 1 / Phase 2 | 46 | Genzyme, a Sanofi CompanyINDUSTRY | 12 | May 16, 2017 | clinicaltrials |
| NCT01241162 | Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma | completed | Phase 1 | 19 | University of LouisvilleOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01125800 | A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB | completed | Phase 1 / Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 6 | Mar 20, 2017 | clinicaltrials |
| NCT01204450 | Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma | terminated | Phase 1 | 7 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 23, 2016 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT00670410 | Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma | terminated | Phase 1 | 15 | Columbia UniversityOTHER | 1 | Jun 24, 2016 | clinicaltrials |
| NCT00049023 | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors | completed | Phase 1 | 27 | O'Dorisio, M SOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT02444884 | MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors | completed | Phase 1 | 54 | Children's Oncology GroupNETWORK | 0 | Feb 9, 2016 | clinicaltrials |
| NCT01169584 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients | completed | Phase 1 | 6 | Jennerex BiotherapeuticsINDUSTRY | 1 | Jan 21, 2016 | clinicaltrials |
| NCT01208454 | Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 2 | Nov 24, 2015 | clinicaltrials |
| NCT00450827 | Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma | completed | Phase 1 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 28, 2015 | clinicaltrials |
| NCT01592045 | ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma | completed | Phase 1 / Phase 2 | 28 | United TherapeuticsINDUSTRY | 1 | Sep 23, 2015 | clinicaltrials |
| NCT01598454 | Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides | completed | Phase 1 | 15 | Laboratorio Elea Phoenix S.A.INDUSTRY | 1 | Jul 29, 2015 | clinicaltrials |
| NCT01174537 | New Castle Disease Virus (NDV) in Glioblastoma Multiforme (GBM), Sarcoma and Neuroblastoma | withdrawn | Phase 1 / Phase 2 | 0 | Hadassah Medical OrganizationOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT00020150 | Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00003484 | Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors | completed | Phase 1 | 21 | Darell D. Bigner, MD, PhDOTHER | 1 | Apr 23, 2015 | clinicaltrials |
| NCT01518413 | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | completed | Phase 1 | 17 | HMeanyOTHER | 1 | Feb 27, 2015 | clinicaltrials |
| NCT01404702 | Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma | terminated | Phase 1 | 4 | University of Alabama at BirminghamOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT00003107 | Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors | completed | Phase 1 | — | Indiana UniversityOTHER | 1 | Sep 10, 2014 | clinicaltrials |
| NCT00003461 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors | completed | Phase 1 / Phase 2 | — | Duke UniversityOTHER | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00003750 | Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors | completed | Phase 1 | 28 | Children's Oncology GroupNETWORK | 3 | Aug 8, 2014 | clinicaltrials |
| NCT00002740 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Followed by Surgery and/or Radiation Therapy in Treating Young Patients With Advanced Neuroblastoma | completed | Phase 1 | 30 | Children's Oncology GroupNETWORK | 1 | Jul 24, 2014 | clinicaltrials |
| NCT00217412 | Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2014 | clinicaltrials |
| NCT00003141 | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors | completed | Phase 1 | 94 | Children's Oncology GroupNETWORK | 3 | Mar 28, 2014 | clinicaltrials |
| NCT00070200 | Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma | completed | Phase 1 | 31 | Children's Oncology GroupNETWORK | 2 | Feb 13, 2014 | clinicaltrials |
| NCT01048892 | Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features | completed | Phase 1 | 22 | Children's Oncology GroupNETWORK | 1 | Jan 30, 2014 | clinicaltrials |
| NCT00101309 | Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma | unknown | Phase 1 | 10 | Milton S. Hershey Medical CenterOTHER | 1 | Dec 18, 2013 | clinicaltrials |
| NCT00028522 | R(+)XK469 in Treating Patients With Advanced Neuroblastoma | completed | Phase 1 | 85 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2013 | clinicaltrials |
| NCT01319838 | Aflac ST1001 Prolonged Isotretinoin(Aflac ST1001) | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 1 | Dec 10, 2013 | clinicaltrials |
| NCT00450307 | Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma | completed | Phase 1 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 16, 2013 | clinicaltrials |
| NCT00075634 | Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00206388 | Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement | completed | Phase 1 | 21 | Baylor College of MedicineOTHER | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00002543 | Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin's Lymphoma, or Refractory Solid Tumors | completed | Phase 1 | 3 | Medical College of WisconsinOTHER | 1 | Jul 18, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Nov 15, 2018source: clinicaltrials